Literature DB >> 17430243

Role of LXR and ABCA1 in the pathogenesis of Alzheimer's disease - implications for a new therapeutic approach.

Radosveta Koldamova1, Iliya Lefterov.   

Abstract

Studies, ranging from epidemiological to in vitro and in vivo experimental settings have provided convincing evidence that different aspects of brain lipid metabolism may influence Alzheimer disease pathogenesis through effects on beta-amyloid deposition and clearance. It has been demonstrated that transcription factors called nuclear liver X receptors (LXR) and their responsive genes provide natural regulatory mechanisms and influence AD pathogenesis through their modulatory effects on intracellular cholesterol content, cholesterol efflux and possibly via anti-inflammatory mechanisms. Here, we provide a brief summary of the approaches undertaken by different groups that lead to the nowadays working model of LXR and ABCA1 regulatory role in brain amyloidogenesis and amyloid clearance and we highlight the therapeutic potential of LXR agonists.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17430243     DOI: 10.2174/156720507780362227

Source DB:  PubMed          Journal:  Curr Alzheimer Res        ISSN: 1567-2050            Impact factor:   3.498


  23 in total

Review 1.  Emerging roles for nuclear receptors in the pathogenesis of age-related macular degeneration.

Authors:  Goldis Malek; Eleonora M Lad
Journal:  Cell Mol Life Sci       Date:  2014-08-26       Impact factor: 9.261

Review 2.  Sterol regulation of metabolism, homeostasis, and development.

Authors:  Joshua Wollam; Adam Antebi
Journal:  Annu Rev Biochem       Date:  2011       Impact factor: 23.643

3.  Hippocampal and cognitive aging across the lifespan: a bioenergetic shift precedes and increased cholesterol trafficking parallels memory impairment.

Authors:  Inga Kadish; Olivier Thibault; Eric M Blalock; Kuey-C Chen; John C Gant; Nada M Porter; Philip W Landfield
Journal:  J Neurosci       Date:  2009-02-11       Impact factor: 6.167

Review 4.  MicroRNAs: a connection between cholesterol metabolism and neurodegeneration.

Authors:  Leigh Goedeke; Carlos Fernández-Hernando
Journal:  Neurobiol Dis       Date:  2014-06-05       Impact factor: 5.996

5.  MiR-106b impairs cholesterol efflux and increases Aβ levels by repressing ABCA1 expression.

Authors:  Jaekwang Kim; Hyejin Yoon; Cristina M Ramírez; Sang-Mi Lee; Hyang-Sook Hoe; Carlos Fernández-Hernando; Jungsu Kim
Journal:  Exp Neurol       Date:  2011-11-18       Impact factor: 5.330

Review 6.  Lipid metabolism emerges as a promising target for malignant glioma therapy.

Authors:  Deliang Guo; Erica Hlavin Bell; Arnab Chakravarti
Journal:  CNS Oncol       Date:  2013-05

7.  Overexpression of ABCA1 reduces amyloid deposition in the PDAPP mouse model of Alzheimer disease.

Authors:  Suzanne E Wahrle; Hong Jiang; Maia Parsadanian; Jungsu Kim; Aimin Li; Amanda Knoten; Sanjay Jain; Veronica Hirsch-Reinshagen; Cheryl L Wellington; Kelly R Bales; Steven M Paul; David M Holtzman
Journal:  J Clin Invest       Date:  2008-02       Impact factor: 14.808

8.  Comment on "ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models".

Authors:  Nicholas F Fitz; Andrea A Cronican; Iliya Lefterov; Radosveta Koldamova
Journal:  Science       Date:  2013-05-24       Impact factor: 47.728

9.  Adeno-associated virus gene therapy with cholesterol 24-hydroxylase reduces the amyloid pathology before or after the onset of amyloid plaques in mouse models of Alzheimer's disease.

Authors:  Eloise Hudry; Debby Van Dam; Wim Kulik; Peter P De Deyn; Femke S Stet; Ornella Ahouansou; Abdellatif Benraiss; André Delacourte; Pierre Bougnères; Patrick Aubourg; Nathalie Cartier
Journal:  Mol Ther       Date:  2009-08-04       Impact factor: 11.454

10.  Proton pump inhibitor lansoprazole is a nuclear liver X receptor agonist.

Authors:  Andrea A Cronican; Nicholas F Fitz; Tam Pham; Allison Fogg; Brionna Kifer; Radosveta Koldamova; Iliya Lefterov
Journal:  Biochem Pharmacol       Date:  2010-01-08       Impact factor: 5.858

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.